[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"foot-ulcers-diabetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:foot-ulcers-diabetic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100589329","phase-4-efficacy-of-plasma-rich-in-growth-factors-prgf-in-the-treatment-of-foot-ulcers-in-diabetic-patients-with-peripheral-arterial-disease-100589329",false,"NCT06952998","Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease","Randomized Clinical Trial, Controlled With Conventional Treatment to Evaluate the Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease","PIEDIABETICO","Inclusion Criteria:\n\n* Patients aged at least 18 years\n* Diagnosis of type 1 or 2 diabetes\n* Presence of one or more ulcers below the malleoli\n* Ulcer size ranging from 1 to 25 cm2\n* Peripheral Arterial Disease (PAD)\n* Meet at least 2 of the following crieria:\n* Absence of peripheral pulses at any level on physical examination of lower extremities\n* Ankle pressure of 50-90 mmHg\n* Finger pressure 30-70 mmHg\n* Ankle-branchial index (ABI) 0.5-0.9\n* Finger-arm index (FIBI) 0.3-0.7\n* Transcutaneous oxygen pressure (TcPO2) 30-59 mmHg\n* Degree of infection of the lesion on IDSA\u002FIWGDF scale not greater than 1\n* Availability of observation during the study period\n* Properly completed patient informed consent\n\nExclusion Criteria:\n\n* Ulcers grade 3 or higher\n* Positive markers for HCV, AfHBs, HIV-I\u002FII or TP\n* Diabetes mellitus with poor metabolic control (evidence of glycosylated hemoglobin \\>9%)\n* Active systemic infection\n* History of cancerous or precancerous lesions in the area of intervention\n* On active treatment with other local treatment at the site of treatment\n* On active treatment with immunosuppressants and\u002For other drugs contraindicating blood collection\n* History of allergy to blood derivatives\n* Previous diagnosis of coagulopathies\n* Regular and continuous treatment (≥ 3 months) with NSAIDs (with the exception of the use of acetylsalicilic acid)\n* Pregnancy or women of chilbearig age not taking effective contraceptive measures. These methods are, according to recommendations of the Clinical Trial Facilitation Group (CTFG) Contraception Working Group (CTFG) (V1.1), the following Hormonal contraception associated with ovulation inhibition, intrauterine decide (IUD), intrauterine hormone-releasing system, bilateral tubal ligation, vasectomy partner, sexual abstinence\n* Breastfeeding women\n* Treatment with monoclonal antibodies\n* Any inabilities to participate in the study","ALL","18 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study is a randomized clinical trial that compares the effectiveness of Plasma Rich in Growth Factors (PRGF) with conventional treatment for healing foot ulcers in diabetic patients who also have peripheral arterial disease. The goal is to assess how well PRGF promotes healing over a six-month period.",[27],"Foot Ulcers, Diabetic","RECRUITING","2025-09-10",{"date":31,"type":32},"2025-09-11","ACTUAL",{"date":34,"type":21},"2025-11-01",{"date":36,"type":21},"2027-05-30",{"name":38,"class":39},"Biotechnology Institute IMASD","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100585882","salacia-salvesan-vs-conventional-management-of-diabetic-foot-wounds-100585882","NCT06908148","SALACIA: SALvesAn vs Conventional Management of dIAbetic Foot Wounds","SALACIA: Randomised Control Trial of SALvesAn Neutral Electrolysed Water Versus Conventional Management of Non-healing dIAbetic Foot Wounds","SALACIA","Inclusion Criteria:\n\n* Adult diabetic patients (18-89 years)\n* Chronic wounds (present for \\>=3 weeks since commencing Podiatry care)\n* Non-healing (wounds that, in the view of the patient's Podiatrist, are not responding to standard treatment)\n* Wounds that are \\>=5mm when measured in any direction\n\nExclusion Criteria:\n\n* Patients lacking capacity to provide informed consent\n* Patients with underlying terminal disease\n* Patients with severe comorbidities, e.g. morbidly obese; uncontrolled diabetes (HbA1c \\> 97 mmol\u002Fmol); gangrene; chronic leg oedema\u002Fvenous disease; end-stage renal disease; untreatable ischaemic heart disease; HIV; etc.\n* Women who are pregnant or breastfeeding will be excluded from this trial.\n* Women of child-bearing potential who are not using an acceptable form of contraception will be excluded from this trial.","89 Years",{"count":51,"type":21},200,[53],"NA","Increasing prevalence of diabetes mellitus has led to increasing numbers of chronic non-healing foot ulcers (wounds).\n\nElectrolysed water is a novel antiseptic which reduces bacterial load and appears to encourage wound healing. The investigators propose to compare electrolysed water against conventional management.",[27,56],"Foot Ulcer Unhealed",[58,59,60,61],"Foot Ulcers","Diabetic","Wound Healing","Electrolysed Water","NOT_YET_RECRUITING","2025-04-01",{"date":65,"type":32},"2025-04-03",{"date":67,"type":21},"2025-07-01",{"date":69,"type":21},"2026-09-01",{"name":71,"class":72},"NHS Lanarkshire","OTHER_GOV"]